Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02611882 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients
A Phase 2 study, sponsored by Thomas Hope.
- Completed
- Registry status
- Phase 2
- Development phase
- 225
- Enrollment target
NCT02611882: Completed Phase 2 study, sponsored by Thomas Hope.
NCT02611882 is a Phase 2 study that has completed, run by Thomas Hope. The registered enrollment target is 225 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (69% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02611882, a Phase 2 study, has completed, sponsored by Thomas Hope.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 225 participants
- Enrollment target
Study Summary
The investigators are imaging patients with prostate cancer using a new PET imaging agent (Ga-68 HBED-CC PSMA) in order to evaluate it's ability to detection prostate cancer in patients with high risk disease prior to prostatectomy, patients with biochemical recurrence and patients with castrate resistant prostate cancer.
Primary Outcome
Patients who have a positive node on imaging and on pathology will be considered a true-positive. Patients who have no nodes on imaging and pathology will be considered true- negatives. Patients with positive nodes on imaging and negative on pathology will be considered false positives and those with positive nodes on pathology but negative on imaging will be considered false negatives. Point estimate of the true positive rate will be calculated with the corresponding 95% confidence interval.
Interventions
- DRUG Ga-68 labeled HBED-CC PSMA
- DEVICE Positron Emission Tomography (PET) image combined with Computed Tomography (CT) (PET/CT)
- DEVICE Positron Emission Tomography (PET) image combined with Magnetic Resonance Imaging (MRI) (PET/MRI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2015-12-18 |
| Est. Completion | 2016-10-24 |
| Phase | Phase 2 |
What the finished NCT02611882 record still lists
NCT02611882 is an interventional study that assigns participants to a tested intervention. The registered 225 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (69% higher).
The record links to 0 conditions, and to 3 interventions - of which Ga-68 labeled HBED-CC PSMA is the first listed.
NCT02611882 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02611882 about?
NCT02611882 is a clinical study titled "Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients". The investigators are imaging patients with prostate cancer using a new PET imaging agent (Ga-68 HBED-CC PSMA) in order to evaluate it's ability to detection prostate cancer in patients with high risk disease prior to prostatectomy, patients with biochemical recurrence and patients with castrate res...
What is the current status of trial NCT02611882?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 225 participants. The study started on 2015-12-18. Estimated completion is 2016-10-24.
What interventions are being tested in trial NCT02611882?
The interventions under investigation include: Ga-68 labeled HBED-CC PSMA (DRUG), Positron Emission Tomography (PET) image combined with Computed Tomography (CT) (PET/CT) (DEVICE), Positron Emission Tomography (PET) image combined with Magnetic Resonance Imaging (MRI) (PET/MRI) (DEVICE).
Who is sponsoring clinical trial NCT02611882?
This trial is sponsored by Thomas Hope, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02611882's enrollment target sits among peer trials
225 267th of 2000 higher than 1,732 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03955445 · 225 participants · Phase 3
Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN
- NCT04054310 · 225 participants · NA
Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
- NCT04480554 · 225 participants · Phase 2
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
- NCT04888104 · 225 participants
Prospective, Multicenter, Case-Control Analysis of the VersaTie Posterior Fixation System to Prevent Proximal Junctional Failure in Long Posterior Spinal Fusion Constructs for Adult Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI